<DOC>
	<DOCNO>NCT02963688</DOCNO>
	<brief_summary>PURPOSE : To investigate prevalence clinical correlation germline BRCA 1/2 mutation Korean patient high grade ( HG ) serous and/or endometrioid epithelial ovarian cancer ( EOC ) . PATIENTS AND METHODS : In nationwide case-control study EOC conduct Korea 2010 2015 , 298 Korean woman HG serous and/or endometrioid EOC test gBRCA 1/2 mutation , regardless family history . Mutation screen perform use Ion AmpliSeq BRCA 1/2 Panel ( Life Technologies , Carlsbad , CA , USA ) Ion PGM platform accord manufacturer 's instruction . Clinical characteristic include survival outcome assess gBRCAm carrier .</brief_summary>
	<brief_title>BRCA 1/2 Mutation Korean Patients With Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>woman 18 year age old previously untreated , HG serous and/or endometrioid EOC , fallopian tube primary peritoneal carcinoma consent genetic testing 2010 2015 woman mucinous , clear cell , lowgrade serous endometrioid , mixed epithelial adenocarcinoma , undiffereniated carcinoma malignant brenner 's tumor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>